Quantcast

Latest Omalizumab Stories

2014-07-31 16:28:27

Conference call today at 4:30 p.m. EDT MONROVIA, Calif., July 31, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2014 and provided a review of recent business highlights. "In the second quarter, we presented preclinical data at the American Thoracic...

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-05-28 08:31:16

MONROVIA, Calif., May 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the first subject has been dosed in a Phase 1a clinical trial of XmAb®7195. XmAb7195 is a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of action as a potential treatment for asthma and...

2014-05-15 08:32:10

Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced it will present preclinical data comparing activity of XmAb®7195 to omalizumab in reducing IgE, a protein responsible...

2014-05-01 12:28:46

Reduction in Exacerbations Remains the Top Driver of Physician Prescribing Choice in Moderate to Severe Asthma, According to Findings from Decision Resources Group BURLINGTON, Mass., May 1, 2014 /PRNewswire/ -- Decision Resources Group finds that 90 percent of surveyed U.S. payers indicated a willingness to pay a premium-price for a novel therapy with substantially greater improvements in reducing exacerbations than Genentech/Novartis's Xolair in the treatment of severe asthma. Surveyed U.S....

2014-03-21 16:23:03

- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years EAST HANOVER, N.J., March 21, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) approved Xolair(®) (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with...

2014-03-19 16:23:41

Conference call to be held today at 4:30 p.m. EDT MONROVIA, Calif., March 19, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of business highlights. "We are very pleased that Xencor now has five clinical...

Food Allergy Oral Immunotherapy More Effective When Paired With Asthma Drug Omalizumab
2014-03-01 04:56:07

Brett Smith for redOrbit.com - Your Universe Online New research from Stanford University and Johns Hopkins Medical School has shown that an asthma drug can be used to help desensitize people to several food allergens all at once, according to a new report in the journal Allergy, Asthma & Clinical Immunology. The new findings expand on previous research from the same team that showed a technique called oral immunotherapy could be used to desensitize someone to multiple food...

2014-02-24 23:03:30

Houston Allergy & Asthma Associates reports new findings from research on more efficient and effective methods to treat asthma. Houston, TX (PRWEB) February 24, 2014 Houston Allergy & Asthma Associates reports new findings from research on more efficient and effective methods to treat asthma. The research, funded by Novartis Pharmaceuticals, appeared in Current Medical Research and Opinion this month. It concerns a novel liquid formulation of the monoclonal antibody omalizumab...

2014-01-20 12:24:00

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth Summary GBI Research, a leading business intelligence provider, has released its latest research report, "Asthma Therapeutics Market to 2019 -...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related